Total Funding
43
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Proclara is pioneering a new approach to treating neurodegenerative diseases.
- Beka Solomon: Co-founder and Scientific Advisor
Kimberley Gannon: SVP Preclinical Research and DevelopmentPast Role: Epix Pharmaceuticals, Senior Director
About the Company
NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It
offers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Women Founded
